ArticlePancreas2025
Long-term Outcomes of Surgical Treatment for Pancreatic Neuroendocrine Neoplasm With Synchronous Hepatic Metastasis: A Multicenter Retrospective Cohort Study.
Article in Pancreas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resection of the primary tumor with or without liver resection reduces the risk of death in patients with liver metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Survival Outcomes in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Progression-Related Endpoints.Cancers · 2026Review
- Automated machine learning predicts liver metastases in patients with early-onset gastroenteropancreatic neuroendocrine tumors.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate surgical impact on the overall survival (OS) of pancreatic neuroendocrine neoplasm (pNEN) with synchronous hepatic metastases (sHMs).
methodsA total of 163 pNEN-sHM patients were recruited from 3 institutions in China, who were categorized into 3 groups: no resection, resection of the primary lesion, and resection of both primary and hepatic lesions (PHR). Cox regression was employed to evaluate surgical impact on the OS.
resultsIn the overall cohort analysis, PHR demonstrated a significant protective effect on OS (hazard ratio, 0.302; 95% confidence interval, 0.127-0.721; P = 0.007). Nevertheless, subgroup analysis revealed PHR conferred a survival advantage in patients with pancreatic neuroendocrine tumor (pNET) located on the pancreatic body/tail (bt-pNET-sHM) (hazard ratio, 0.287; 95% CI, 0.087-0.946; P = 0.040), whereas surgical treatment did not significantly impact survival in the subgroups of pancreatic neuroendocrine carcinoma-sHM or pancreatic head/neck pNET-sHM (hn-pNET-sHM).
conclusionsIn this study, the survival benefit of surgery was observed only in the bt-pNET-sHM subgroup. Considering the multifactorial nature of decision-making, surgical intervention for pNEN-sHM management should be approached with a careful and comprehensive assessment, to prevent excessive surgery strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.